Kajalakshmy M 2022. Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes. Journal for ReAttach Therapy and Developmental Diversities. 5, 2 (Dec. 2022), 788–792. DOI:https://doi.org/10.53555/jrtdd.v5i2.3854.